Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Unkel, Steffen ^a   Röver, Christian ^a   Stallard, Nigel ^b   Benda, Norbert ^c   Posch, Martin ^d   Zohar, Sarah ^e   Friede, Tim ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c Federal Institute for Drugs and Medical Devices   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e INSERM   (France)

Author keywords

Clinical trials; Creutzfeldt Jakob disease; Evidence synthesis; Paediatric multiple sclerosis; Rare diseases; Systematic review

Indexed keywords

ARTICLE; CREUTZFELDT JAKOB DISEASE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL ASSESSMENT; METHODOLOGY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; ONSET AGE; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; CREUTZFELDT-JAKOB SYNDROME;

CREUTZFELDT-JAKOB SYNDROME; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84958279685     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0402-6     Document Type: Article

References (63)

1. Orphan Medicinal Product Regulation. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J. 2000;L 18:15.
2. European Commission [Internet]. Brussels: Directorate-General for Health and Food Safety [cited 2015 Mar 20]. Available from: http://ec.europa.eu/health/rare-diseases/policy/.
3. Editorial. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011;10(2):109.
4. Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013;163(3):631-7.
5. Orphanet [Internet]. Paris [updated 2015 July]. [cited 2015 Aug 7]. Available from: http://www.orpha.net.
6. Kornek B. Treatment of pediatric multiple sclerosis. Neuropediatrics. 2013;44:309-13.
7. National Multiple Sclerosis Society [Internet]. New York City [cited 2015 Apr 21]. Available from: http://www.nationalmssociety.org/.
8. Orphanet Report Series. Prevalence of rare diseases: bibliographic data, vol. 1. 2014.
9. Creutzfeldt-Jakob disease fact sheet. National Institute of Neurological Disorders and Stroke. Bethesda, MD [cited 2015 Apr 21]. Available from: http://www.ninds.nih.gov/disorders/cjd/detail-cjd.htm.
10. Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95:265-8.
11. De la Paz MP, Villaverde-Hueso A, Alonso V, János S, Zurriaga O, Pollán M, et al. Rare diseases epidemiology research. Adv Exp Med Biol. 2010;686:17-39.
12. European Medicines Agency (EMA). Guideline on clinical trials in small populations. London:European Medicines Agency; 2006.
13. Korn EL, Freidlin B. Outcome-adaptive randomization: Is it useful? J Clin Oncol. 2011;29(6):771-6.
14. Johannessen T. Controlled trials in single subjects. 1. Value in clinical medicine. BMJ. 1991;303(6795):173-4.
15. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: Wiley; 2004.
16. Food and Drug Administration (FDA). Rare diseases: common issues in drug development. Draft guidance for industry. Silver Spring, Maryland:Food and Drug Administration; 2015.
17. Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.
18. Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5(178):178sr3.
19. Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62:1006-12.
21. Wieseler B, McGauran N. Reporting a systematic review. Chest. 2010;137(5):1240-6.
22. Higgins JPT, Altman DG, Sterne, JAC (editors). Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.cochrane-handbook.org.
23. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org.
24. Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology. 2009;72:8-10.
25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
26. Bykova OV, Studenikin VM, Kuzenkova LM, Maslova OI, Boko AN. Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Spec No 3:116-21.
27. Bykova OV, Kuzenkova LM, Maslova OI. The use of beta-interferon-1b in children and adolescents with multiple sclerosis. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(9):29-33.
28. Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 2006;37(4):257-60.
29. Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009;30(3):193-9.
30. Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci. 2007;28(3):127-32.
31. Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci. 2005;26 Suppl 4:S183-6.
32. Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420-4.
33. Day SJ, Graham DF. Sample size and power for comparing two or more treatment groups in clinical trials. BMJ. 1989;299(6700):663-5.
34. Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849-56.
35. Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472-6.
36. Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888-90.
37. Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008;12(3):205-9.
38. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double blind study. Neurology. 2004;62(5):714-8.
39. Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015-23.
40. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334-44.
41. Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150-8.
42. Collett D. Modelling survival data in medical research. 3rd ed. Boca Raton: Chapman & Hall/CRC; 2015.
43. Tagliavini F. Prion therapy: tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers Dement. 2008;4(suppl):T149-50.
44. Haïk S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Lauprêtre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63(12):2413-5.
45. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116-27.
46. Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.
47. Evans CH Jr, Ildstad ST, editors. Small Clinical Trials: Issues and Challenges. Washington, D. C.:National Academies Press; 2001.
48. Tenembaum SN. Ethical challenges in paediatric clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2012;5(3):139-46.
49. EMA [Internet]. London. [cited 2015 July 21]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/PIP-decision/WC500143702.pdf.
50. O'Hagan A, Buck CE, Daneshkhah A, et al. Uncertain judgements: Eliciting Experts' Probabilities. Chichester: Wiley; 2006.
51. Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med. 2014;33(24):4186-201.
52. Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome. Clin Trials. 2005;2(4):305-10.
53. European Medicines Agency (EMA). Concept paper on extrapolation of efficacy and safety in medicine development. London:European Medicines Agency; 2012.
54. Food and Drug Administration (FDA). Leveraging existing clinical data for extrapolation to pediatric uses of medical devices. Draft guidance. Silver Spring, Maryland:Food and Drug Administration; 2015.
55. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705-13.
56. Gross O, Friede T, Hilgers R, Görlitz A, Gavénis K, Ahmed R, et al. Safety and efficacy of the ace-inhibitor ramipril in alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT alport trial in pediatric patients. ISRN Pediatr. 2012;2012:436046.
57. Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Krasnianski A, et al. Doxycycline in early Creutzfeldt-Jakob disease - double-blinded randomized phase II and observational study. 2015. Submitted for publication.
58. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Chichester: Wiley; 2012.
59. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials. 2010;7:5-18.
60. Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19(8):1106-12.
61. Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70(4):469-75.
62. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511-3.
63. Fincke F. Doxycyclin bei der sporadischen Creutzfeldt-Jakob-Krankheit. PhD thesis. Goettingen:University Medical Center Goettingen; 2010.